ResMed Inc. vs United Microelectronics Corp — how do they compare? ResMed Inc. trades at $222.7 (market cap $32.61B), while United Microelectronics Corp trades at $19.52 (market cap $47.81B). The key difference: United Microelectronics Corp is the larger of the two by market cap, and United Microelectronics Corp pays the higher dividend (2.12%). Which is the better fit depends on your goals.
| RMD | UMC | |
|---|---|---|
Market Cap | $32.61B | $47.81B |
Sector | Health | Technology |
52-Week High | $293.73 | $28.02 |
52-Week Low | $182.82 | $6.58 |
Enterprise Value | $31.97B | $44.93B |
Dividend Yield | 1.17% | 2.12% |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
UMC trades at $18.79, up 0.37% today, with a bearish technical signal. Recent earnings beats and strong July 2026 sales growth of 18.98% year-over-year highlight operational momentum. The company is expanding capacity in Singapore and Taiwan to meet AI-driven demand, supported by a robust balance sheet with $115.24 billion in cash. However, net income margin has declined from 32.1% in 2022 to 16.99% in 2025, posing a concern.
The outlook is mixed; expansion initiatives and AI tailwinds offer growth potential, but margin compression and a bearish technical stance present risks. Analyst consensus is cautious with 53.33% hold ratings. Key catalysts include Q3 2026 earnings and fab expansion progress, while competitive pressures and macroeconomic volatility remain headwinds.
Trailing returns across standard periods
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →